{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:14Z","timestamp":1794047474418,"version":"4.8.0"},"reference-count":52,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"11","license":[{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Non-Hodgkin lymphomas (NHL) commonly occur in immunodeficient patients, both those infected by human immunodeficiency virus (HIV) and those who have been transplanted, and are often driven by Epstein-Barr virus (EBV) with cerebral localization, raising the question of tumor immunogenicity, a critical issue for treatment responses. We investigated the immunogenomics of 68 lymphoproliferative disorders from 51 immunodeficient (34 post-transplant, 17 HIV+) and 17 immunocompetent patients. Overall, 72% were large B-cell lymphoma and 25% were primary central nervous system lymphoma, while 40% were EBV+. Tumor whole-exome and RNA sequencing, along with a bioinformatics pipeline allowed analysis of tumor mutational burden, tumor landscape and tumor microenvironment and prediction of tumor neoepitopes. Both tumor mutational burden (2.2 vs. 3.4\/Mb, P=0.001) and numbers of neoepitopes (40 vs. 200, P=0.00019) were lower in EBV+ than in EBV\u2013 NHL, regardless of the immune status. In contrast both EBV and the immune status influenced the tumor mutational profile, with HNRNPF and STAT3 mutations observed exclusively in EBV+ and immunodeficient NHL, respectively. Peripheral blood T-cell responses against tumor neoepitopes were detected in all EBV\u2013 cases but in only half of the EBV+ ones, including responses against IgH-derived MHC-class-II restricted neoepitopes. The tumor microenvironment analysis showed higher CD8 T-cell infiltrates in EBV+ versus EBV\u2013 NHL, together with a more tolerogenic profile composed of regulatory T cells, type-M2 macrophages and an increased expression of negative immune-regulators. Our results highlight that the immunogenomics of NHL in patients with immunodeficiency primarily relies on the tumor EBV status, while T-cell recognition of tumor- and IgH-specific neoepitopes is conserved in EBV\u2013 patients, offering potential opportunities for future T-cell-based immune therapies.<\/jats:p>","DOI":"10.3324\/haematol.2023.284332","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T15:38:20Z","timestamp":1717688300000},"page":"3615-3630","source":"Crossref","is-referenced-by-count":5,"title":["Epstein-Barr virus and immune status imprint the immunogenomics of non-Hodgkin lymphomas occurring in immune-suppressed environments"],"prefix":"10.3324","volume":"109","author":[{"given":"Marine","family":"Baron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Labreche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Veyri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"D\u00e9sir\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira","family":"Bouzidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatou","family":"Seck-Thiam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Charlotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Morin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cilia","family":"Nakid-Cordero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Abbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Picca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Le Cann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noureddine","family":"Balegroune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Theodorou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Touat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Bielle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assia","family":"Samri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agusti","family":"Alentorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Sanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Roos-Weil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Haioun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Poullot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Langlois","family":"De Septenville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Davi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Guihot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Yves","family":"Boelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Leblond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Coulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Spano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Choquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Autran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"IDeATIon","family":"Study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"key":"68421","doi-asserted-by":"crossref","unstructured":"Engels EA. Cancer in solid organ transplant recipients: there is still much to learn and do. Am J Transplant. 2017; 17(8):1967-1969.","DOI":"10.1111\/ajt.14140"},{"key":"68422","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez-Ram\u00edrez RU, Shiels MS, Dubrow R, Engels EA. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV. 2017; 4(11):e495-e504.","DOI":"10.1016\/S2352-3018(17)30125-X"},{"key":"68423","doi-asserted-by":"crossref","unstructured":"Blosser CD, Haber G, Engels EA. Changes in cancer incidence and outcomes among kidney transplant recipients in the United States over a thirty-year period. Kidney Int. 2021; 99(6):1430-1438.","DOI":"10.1016\/j.kint.2020.10.018"},{"key":"68424","doi-asserted-by":"crossref","unstructured":"Carbone A, Vaccher E, Gloghini A. Hematologic cancers in individuals infected by HIV. Blood. 2022; 139(7):995-1012.","DOI":"10.1182\/blood.2020005469"},{"key":"68425","doi-asserted-by":"crossref","unstructured":"Dharnidharka VR, Webster AC, Martinez OM, Preiksaitis JK, Leblond V, Choquet S. Post-transplant lymphoproliferative disorders. Nat Rev Dis Primers. 2016; 2(1):15088.","DOI":"10.1038\/nrdp.2015.88"},{"key":"68426","doi-asserted-by":"crossref","unstructured":"Finalet Ferreiro J, Morscio J, Dierickx D. EBV-positive and EBV-negative posttransplant diffuse large B cell lymphomas have distinct genomic and transcriptomic features: genetics of PTLD. Am J Transplant. 2016; 16(2):414-425.","DOI":"10.1111\/ajt.13558"},{"key":"68427","doi-asserted-by":"crossref","unstructured":"Gandhi MK, Hoang T, Law SC. EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity. Blood. 2021; 137(11):1468-1477.","DOI":"10.1182\/blood.2020008520"},{"key":"68428","doi-asserted-by":"crossref","unstructured":"Menter T, Juskevicius D, Alikian M. Mutational landscape of B-cell post-transplant lymphoproliferative disorders. Br J Haematol. 2017; 178(1):48-56.","DOI":"10.1111\/bjh.14633"},{"key":"68429","doi-asserted-by":"crossref","unstructured":"Yoon H, Park S, Ju H. Integrated copy number and gene expression profiling analysis of Epstein-Barr virus-positive diffuse large B-cell lymphoma. Genes Chromosomes Cancer. 2015; 54(6):383-396.","DOI":"10.1002\/gcc.22249"},{"key":"68430","doi-asserted-by":"crossref","unstructured":"Kaulen LD, Denisova E, Hinz F. Integrated genetic analyses of immunodeficiency-associated Epstein-Barr virus- (EBV) positive primary CNS lymphomas. Acta Neuropathol. 2023; 146(3):499-514.","DOI":"10.1007\/s00401-023-02613-w"},{"key":"68431","doi-asserted-by":"crossref","unstructured":"Guney E, Lucas C-HG, Singh K. Molecular profiling identifies at least 3 distinct types of posttransplant lymphoproliferative disorder involving the CNS. Blood Adv. 2023; 7(13):3307-3311.","DOI":"10.1182\/bloodadvances.2022009521"},{"key":"68432","doi-asserted-by":"crossref","unstructured":"Nakid-Cordero C, Arzouk N, Gauthier N. Skewed T cell responses to Epstein-Barr virus in long-term asymptomatic kidney transplant recipients. PLoS One. 2019; 14(10):e0224211.","DOI":"10.1371\/journal.pone.0224211"},{"key":"68433","doi-asserted-by":"crossref","unstructured":"Nakid-Cordero C, Choquet S, Gauthier N. Distinct immunopathological mechanisms of EBV-positive and EBV-negative posttransplant lymphoproliferative disorders. Am J Transplant. 2021; 21(8):2846-2863.","DOI":"10.1111\/ajt.16547"},{"key":"68434","doi-asserted-by":"crossref","unstructured":"Green MR, Rodig S, Juszczynski P. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and post-transplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res. 2012; 18(6):1611-1618.","DOI":"10.1158\/1078-0432.CCR-11-1942"},{"key":"68435","doi-asserted-by":"crossref","unstructured":"Nicolae A, Pittaluga S, Abdullah S. EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment. Blood. 2015; 126(7):863-872.","DOI":"10.1182\/blood-2015-02-630632"},{"key":"68436","doi-asserted-by":"crossref","unstructured":"Keane C, Tobin J, Gunawardana J. The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma. Eur J Haematol. 2019; 103(3):200-207.","DOI":"10.1111\/ejh.13274"},{"key":"68437","doi-asserted-by":"crossref","unstructured":"Keane C, Gould C, Jones K. The T-cell receptor repertoire influences the tumor microenvironment and is associated with survival in aggressive B-cell lymphoma. Clin Cancer Res. 2017; 23(7):1820-1828.","DOI":"10.1158\/1078-0432.CCR-16-1576"},{"key":"68438","doi-asserted-by":"crossref","unstructured":"Dierickx D, Habermann TM. Post-transplantation lymphoproliferative disorders in adults. N Engl J Med. 2018; 378(6):549-562.","DOI":"10.1056\/NEJMra1702693"},{"key":"68439","doi-asserted-by":"crossref","unstructured":"Li L, Goedegebuure SP, Gillanders WE. Preclinical and clinical development of neoantigen vaccines. Ann Oncol. 2017; 28(Suppl_12):xii11-xii17.","DOI":"10.1093\/annonc\/mdx681"},{"key":"68440","doi-asserted-by":"crossref","unstructured":"Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015; 348(6230):69-74.","DOI":"10.1126\/science.aaa4971"},{"key":"68441","doi-asserted-by":"crossref","unstructured":"Yarchoan M, Johnson BA, Lutz ER, Laheru DA, Jaffee EM. Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer. 2017; 17(4):209-222.","DOI":"10.1038\/nrc.2016.154"},{"key":"68442","doi-asserted-by":"crossref","unstructured":"Brown SD, Warren RL, Gibb EA. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res. 2014; 24(5):743-750.","DOI":"10.1101\/gr.165985.113"},{"key":"68443","doi-asserted-by":"crossref","unstructured":"Rizvi H, Sanchez-Vega F, La K. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol. 2018; 36(7):633-641.","DOI":"10.1200\/JCO.2017.75.3384"},{"key":"68444","doi-asserted-by":"crossref","unstructured":"Rizvi NA, Hellmann MD, Snyder A. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-128.","DOI":"10.1126\/science.aaa1348"},{"key":"68445","doi-asserted-by":"crossref","unstructured":"Leidner R, Sanjuan Silva N, Huang H. Neoantigen T-cell receptor gene therapy in pancreatic cancer. N Engl J Med. 2022; 386(22):2112-2119.","DOI":"10.1056\/NEJMoa2119662"},{"key":"68446","doi-asserted-by":"crossref","unstructured":"Li F, Deng L, Jackson KR. Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. J Immunother Cancer. 2021; 9(7):e002531.","DOI":"10.1136\/jitc-2021-002531corr1"},{"key":"68447","doi-asserted-by":"crossref","unstructured":"Platten M, Bunse L, Wick A. A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature. 2021; 592(7854):463-468.","DOI":"10.1038\/s41586-021-03363-z"},{"key":"68448","doi-asserted-by":"crossref","unstructured":"Sahin U, Derhovanessian E, Miller M. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017; 547(7662):222-226.","DOI":"10.1038\/nature23003"},{"key":"68449","doi-asserted-by":"crossref","unstructured":"Khodadoust MS, Olsson N, Wagar LE. Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. Nature. 2017; 543(7647):723-727.","DOI":"10.1038\/nature21433"},{"key":"68450","doi-asserted-by":"crossref","unstructured":"Khodadoust MS, Olsson N, Chen B. B-cell lymphomas present immunoglobulin neoantigens. Blood. 2019; 133(8):878-881.","DOI":"10.1182\/blood-2018-06-845156"},{"key":"68451","doi-asserted-by":"crossref","unstructured":"Bolotin DA, Poslavsky S, Mitrophanov I. MiXCR: software for comprehensive adaptive immunity profiling. Nat Methods. 2015; 12(5):380-381.","DOI":"10.1038\/nmeth.3364"},{"key":"68452","doi-asserted-by":"crossref","unstructured":"Andreatta M, Nielsen M. Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics. 2016; 32(4):511-517.","DOI":"10.1093\/bioinformatics\/btv639"},{"key":"68453","doi-asserted-by":"crossref","unstructured":"Jensen KK, Andreatta M, Marcatili P. Improved methods for predicting peptide binding affinity to MHC class II molecules. Immunology. 2018; 154(3):394-406.","DOI":"10.1111\/imm.12889"},{"key":"68454","doi-asserted-by":"crossref","unstructured":"Steen CB, Liu CL, Alizadeh AA, Newman AM. Profiling cell type abundance and expression in bulk tissues with CIBERSORTx. Methods Mol Biol. 2020; 2117:135-157.","DOI":"10.1007\/978-1-0716-0301-7_7"},{"key":"68455","doi-asserted-by":"crossref","unstructured":"Newman AM, Liu CL, Green MR. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12(5):453-457.","DOI":"10.1038\/nmeth.3337"},{"key":"68456","doi-asserted-by":"crossref","unstructured":"Australian Pancreatic Cancer Genome Initiative ICGC Breast Cancer Consortium ICGC MMML-Seq Consortium. Signatures of mutational processes in human cancer. Nature. 2013; 500(7463):415-421.","DOI":"10.1038\/nature12477"},{"key":"68457","doi-asserted-by":"crossref","unstructured":"Chapuy B, Stewart C, Dunford AJ. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018; 24(5):679-690.","DOI":"10.1038\/s41591-018-0016-8"},{"key":"68458","doi-asserted-by":"crossref","unstructured":"Schmitz R, Wright GW, Huang DW. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018; 378(15):1396-1407.","DOI":"10.1056\/NEJMoa1801445"},{"key":"68459","doi-asserted-by":"crossref","unstructured":"Luskin MR, Heil DS, Tan KS. The impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder. Am J Transplant. 2015; 15(10):2665-2673.","DOI":"10.1111\/ajt.13324"},{"key":"68460","doi-asserted-by":"crossref","unstructured":"Trappe RU, Dierickx D, Zimmermann H. Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase II trial. J Clin Oncol. 2017; 35(5):536-543.","DOI":"10.1200\/JCO.2016.69.3564"},{"key":"68461","doi-asserted-by":"crossref","unstructured":"Zimmermann H, Koenecke C, Dreyling MH. Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell post-transplant lymphoproliferative disorder (PTLD) after solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial. Leukemia. 2022; 36(10):2468-2478.","DOI":"10.1038\/s41375-022-01667-1"},{"key":"68462","doi-asserted-by":"crossref","unstructured":"Ferla V, Rossi FG, Goldaniga MC, Baldini L. Biological difference between Epstein-Barr virus positive and negative post-transplant lymphoproliferative disorders and their clinical impact. Front Oncol. 2020; 10:506.","DOI":"10.3389\/fonc.2020.00506"},{"key":"68463","doi-asserted-by":"crossref","unstructured":"Gross H, Hennard C, Masouris I. Binding of the heterogeneous ribonucleoprotein K (hnRNP K) to the Epstein-Barr virus nuclear antigen 2 (EBNA2) enhances viral LMP2A expression. PLoS One. 2012; 7(8):e42106.","DOI":"10.1371\/journal.pone.0042106"},{"key":"68464","doi-asserted-by":"crossref","unstructured":"Chapman JR, Bouska AC, Zhang W. EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK\/STAT (STAT3) pathway mutations and unique clinicopathologic features. Br J Haematol. 2021; 194(5):870-878.","DOI":"10.1111\/bjh.17708"},{"key":"68465","doi-asserted-by":"crossref","unstructured":"Sarkozy C, Hung SS, Chavez EA. Mutational landscape of gray zone lymphoma. Blood. 2021; 137(13):1765-1776.","DOI":"10.1182\/blood.2020007507"},{"key":"68466","doi-asserted-by":"crossref","unstructured":"Ramis-Zaldivar JE, Gonzalez-Farre B, Nicolae A. MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma. Haematologica. 2021; 106(10):2682-2693.","DOI":"10.3324\/haematol.2020.271957"},{"key":"68467","doi-asserted-by":"crossref","unstructured":"Liu Z, Filip I, Gomez K. Genomic characterization of HIV-associated plasmablastic lymphoma identifies pervasive mutations in the JAK-STAT pathway. Blood Cancer Discov. 2020; 1(1):112-125.","DOI":"10.1158\/2643-3230.BCD-20-0051"},{"key":"68468","doi-asserted-by":"crossref","unstructured":"Leeman-Neill RJ, Soderquist CR, Montanari F. Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas. Haematologica. 2022; 107(1):201-210.","DOI":"10.3324\/haematol.2020.267294"},{"key":"68469","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez-Verdin I, Kirasic E, Wienand K. Molecular and clinical diversity in primary central nervous system lymphoma. Ann Oncol. 2023; 34(2):186-199.","DOI":"10.1016\/j.annonc.2022.11.002"},{"key":"68470","doi-asserted-by":"crossref","unstructured":"Garcia Alvarez HM, Ko\u015falo\u011flu-Yal\u00e7\u0131n Z, Peters B, Nielsen M. The role of antigen expression in shaping the repertoire of HLA presented ligands. iScience. 2022; 25(9):104975.","DOI":"10.1016\/j.isci.2022.104975"},{"key":"68471","doi-asserted-by":"crossref","unstructured":"Wells DK, van Buuren MM, Dang KK. Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction. Cell. 2020; 183(3):818-834.","DOI":"10.1016\/j.cell.2020.09.015"},{"key":"68472","doi-asserted-by":"crossref","unstructured":"De Mattos-Arruda L, Vazquez M, Finotello F. Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group. Ann Oncol. 2020; 31(8):978-990.","DOI":"10.1016\/j.annonc.2020.05.008"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284332\/77117","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284332\/77706","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11634\/77117","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:06:38Z","timestamp":1794045998000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,6]]},"references-count":52,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284332","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,6]]}}}